ones. i am searching for the companies that i like that can thrive inthisenvironmentwiththe fiscal cliff and a recession a possibility. look, u.it it's a possibility. today i was throwing a surprise party for amgen. you know what, miscafiscal clif fiscal cliff, we're still having an amgen party here. inappropriate balloon movement there. they make all kinds of drugs for serious illnesses. it has 70 products in development that are starting phase three clinical trials in the early part of next year. phase three means it's getting through fruition. amgen could double earnings per share over the next eight years. that is much better than a sharp stick in the retina. amgen reported on october 23rd after the close and the company delivered spectacular results and was a true triple play. came in $1.67, and revenues 5.9% year over year. when the street was looking for 4.25 billion. and four-year guidance, substantially higher than the analysts expecting. those were fabulous numbers. no surprise that the stock shot up from $87.32, to nearly 90 in after hours trading. however, the next day